Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.52 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15327933 | 0.84 | MAPK1 (0.54) | MAPK1PARP1PARP2PARP3GAA | |
| SCHEMBL29908855 | 0.84 | PARP1 (0.44) | MAPK1PARP1L3MBTL1KDM4EKMT2A | |
| SCHEMBL15328201 | 0.84 | MAPK1 (0.47) | MAPK1PARP1PARP2PARP3GAA | |
| SCHEMBL1396731 | 0.82 | MAPK1 (0.58) | MAPK1PARP1PARP2PARP3L3MBTL1 | |
| SCHEMBL29908864 | 0.81 | KDM4E (0.51) | PARP1GAAKDM4EHTR1AKMT2A | |
| Hydrochloric Acid SCHEMBL29908833 | 0.81 | MAPK1 (0.56) | MAPK1PARP1PARP2PARP3L3MBTL1 | |
| SCHEMBL29815065 | 0.80 | ALDH1A1 (0.51) | MAPK1PARP1GAAKDM4EMEN1 | |
| SCHEMBL5510400 | 0.80 | ALDH1A1 (0.51) | MAPK1PARP1GAAKDM4EMEN1 | |
| SCHEMBL15328325 | 0.77 | ALDH1A1 (0.45) | MAPK1PLA2G1BL3MBTL1ATG4BKDM4E | |
| SCHEMBL30716457 | 0.77 | GAA (0.51) | MAPK1PARP1PARP2PARP3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | MAPK1 106/4885PARP1 1013/4885PARP2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.